Ocular Therapeutix (Ocular Therapeutix) Days Sales Outstanding

: 153.41 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Ocular Therapeutix's average Accounts Receivable for the three months ended in Dec. 2023 was $24.88 Mil. Ocular Therapeutix's Revenue for the three months ended in Dec. 2023 was $14.80 Mil. Hence, Ocular Therapeutix's Days Sales Outstanding for the three months ended in Dec. 2023 was 153.41.

The historical rank and industry rank for Ocular Therapeutix's Days Sales Outstanding or its related term are showing as below:

OCUL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.16 Med: 129.35 Max: 155.2
Current: 149.3

During the past 12 years, Ocular Therapeutix's highest Days Sales Outstanding was 155.20. The lowest was 39.16. And the median was 129.35.

OCUL's Days Sales Outstanding is ranked worse than
77.79% of 887 companies
in the Biotechnology industry
Industry Median: 72.66 vs OCUL: 149.30

Ocular Therapeutix's Days Sales Outstanding increased from Dec. 2022 (133.32) to Dec. 2023 (153.41).

Ocular Therapeutix Days Sales Outstanding Historical Data

The historical data trend for Ocular Therapeutix's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

118.69

155.20

140.00

150.48

148.34

Ocular Therapeutix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																133.32	144.81	145.51	153.98	153.41

Competitive Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocular Therapeutix Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Days Sales Outstanding falls into.

Ocular Therapeutix Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Ocular Therapeutix's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (21.325	+	26.179)	/	2 )	/	58.443	*	365
=	23.752					/	58.443	*	365
=	148.34

Ocular Therapeutix's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (23.589	+	26.179)	/	2 )	/	14.801	*	365 / 4
=	24.884					/	14.801	*	365 / 4
=	153.41

Ocular Therapeutix (NAS:OCUL) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Ocular Therapeutix Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocular Therapeutix (Ocular Therapeutix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

0OT:Germany 0OT:Germany

Address

24 Crosby Drive, Bedford, MA, USA, 01730

Website

https://www.ocutx.com

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Executives

Summer Road Llc	10 percent owner	207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves	director	125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden	officer: Chief Medical Officer	C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger	officer: General Counsel	24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman	officer: Chief Financial Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White	officer: Chief Business Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen	officer: Chief Operations Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney	director, 10 percent owner, officer: President and CEO	C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730